NCT00702520View on ClinicalTrials.gov

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2006

Primary Completion Date

November 7, 2007

Study Completion Date

January 15, 2008

Conditions
PregnancyNeonates
Interventions
DRUG

Corifollitropin alpha (MK-8962, Org 36286) 100 ug

Subcutaneous administration of corifollitropin alpha at a dose of 100 ug

DRUG

Corifollitropin alpha (MK-8962, Org 36286) 150 ug

Subcutaneous administration of corifollitropin alpha at a dose of 150 ug

DRUG

Triptorelin

Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).

BIOLOGICAL

Recombinant follicle stimulating hormone (recFSH)

From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.

BIOLOGICAL

Human chorionic gonadotprophin (hCG).

HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00702520 - Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783) | Biotech Hunter | Biotech Hunter